Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases

Status:	Active, not recruiting
Conditions:	Lung Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	1 - Any
Updated:	9/2/2018
Start Date:	July 2014
End Date:	July 2019

The purpose of this study is to find out what effects, good and/or bad, radiation has on the
lungs has on the patient and on synovial sarcoma which has spread to the lungs. The standard
treatment for synovial sarcoma which has spread to the lungs is chemotherapy with or without
surgery to remove the tumors in the lungs. However, tumors often come back in the lungs after
chemotherapy and/or surgery. Since synovial sarcoma is known to be sensitive to radiation,
this study is looking at whether radiation therapy which is targeted to the entire lung can
further reduce the chances of the cancer returning. This type of radiation is commonly used
in other types of sarcoma to treat the cancer once it has spread to the lungs and it may be
very useful in synovial sarcoma as well.

In this study, a special type of radiation will be used, called Intensity Modulated Radiation
Therapy (IMRT). With IMRT the radiation beams are more customized to focus more radiation on
the tumor cells while delivering less radiation to areas like the heart. The goal of this
study is also to measure pulmonary toxicity and see if IMRT is feasible and has less
toxicity.

Inclusion Criteria:

- Patients with synovial sarcoma confirmed by MSKCC pathological review

- Patients with single or multiple lung metastases at diagnosis or that develop over the
course of treatment. After completion of all chemotherapy, lung metastases or must be
≤ 2cm.

- Age ≥12 months of age

- Karnofsky performance status (KPS) must be ≥ 70 for patients ≥ 16 years of age and
Lansky performance status must be ≥ 70 for patients < 16 years of age.

- Normal cardiac function

- No active coronary artery disease;

- No New York Heart Association class II, III or IV disease;

- No arrhythmia requiring treatment.

- Baseline echocardiogram with a shortening fraction of ≥27% or an ejection fraction ≥
50%.

- Female patients of childbearing potential must have a negative pregnancy test within
14 days of radiation start.

- Female patients who are lactating must agree to stop breast-feeding.

- Sexually active patients of childbearing potential must agree to use effective
contraception.

Exclusion Criteria:

- Patients with a history of prior radiation therapy to the thorax.

- Patients requiring a field size >40 cm as IMRT cannot be performed at extended SSDs.

- Patients with any concurrent medical or psychiatric condition or disease which, in the
investigator's judgment, would make them inappropriate candidates for entry into this
study.

We found this trial at

sites

Memorial Sloan Kettering at Basking Ridge

Basking Ridge, New Jersey 07920

from

Basking Ridge, NJ